Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis

被引:271
|
作者
Bonkovsky, HL
Jawaid, Q
Tortorelli, K
LeClair, P
Cobb, J
Lambrecht, RW
Banner, BF
机构
[1] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA
[2] Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01655 USA
[3] Univ Massachusetts, Ctr Study Disorders Iron & Porphyrin Metab, Worcester, MA 01605 USA
[4] Univ Massachusetts, Ctr Liver, Worcester, MA 01605 USA
[5] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA
关键词
hemochromatosis; hepatic fibrosis; HFE gene; iron; iron overload; mutational analyses; non-alcoholic steatohepatitis; oxidative stress; pathogenesis; restriction fragment length polymorphism(s);
D O I
10.1016/S0168-8278(99)80032-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Non-alcoholic steatohepatitis (NASH) is increasingly recognized, and its pathogenesis is believed to involve increased oxidative stress. Elevated levels of serum ferritin and positive liver iron stains are often observed in patients with NASH, and the pathogenesis of liver injury due to iron is also thought to involve oxidative stress. The aim of this study was to determine whether there is an association of NASH and mutations in the HFE gene associated with hereditary hemochromatosis (HHC). Methods: clinical, laboratory and histopathological data on all 57 subjects with a final diagnosis of NASH seen between August 1990 and August 1997 at our Liver Center were analyzed. Thirty-six Caucasian subjects (23 men) with NASH underwent mutational analyses of HFE gene mutations performed. The prevalence of HFE gene mutations was compared to that in 348 Caucasian normal controls. Data were analyzed by both parameteric and non-parametric methods with similar results. Results: One subject (2.8%) with NASH was homozygous for the C282Y mutation and six (16.7%) mere heterozygous, compared with 0% and 11.2%, respectively, of controls. Two (5.6%) subjects with NASH were homozygous for the H63D mutation and 16 (44.4%) were heterozygous, whereas 2.9% and 26.4%, respectively, of controls had these genotypes. The prevalence of heterozygosity (61.1%) for either mutation was significantly higher in subjects with NASH than in controls (38%) (p=0.008), and the prevalence of homozygosity or heterozygosity combined in NASH subjects (69.4%) was significantly higher than for controls (40.5%, p=0.001). Sex (63-67% male) and age at diagnosis of NASH did not differ between those with or without HFE mutations, but men with NASH were significantly more likely than women to have the H63D mutation (15/23 vs. 3/13, p<0.05) Levels of serum ferritin, iron, transferrin saturation levels, and the degree of hepatic iron staining were significantly higher (p<0.05) in subjects with NASH who carried an HFE mutation than in those without. Differences in hepatic iron concentrations or hepatic iron indices between NASH subjects with and without HFE mutations were not significant. Those with C282Y mutations had significantly more hepatic fibrosis than those without (p<0.05). Those with HFE mutations had significantly higher levels of serum ALT (90+/-11 [mean+/-SE]) than those without (55+/-6; p=0.02). Conclusion: The prevalences of the HFE gene mutations associated with hereditary hemochromatosis are increased among North American subjects with NASH.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 50 条
  • [21] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    [J]. STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [22] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    [J]. STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [23] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810
  • [24] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852
  • [25] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    [J]. LANCET, 2001, 358 (9285): : 893 - 894
  • [26] Fructose and Non-Alcoholic Steatohepatitis
    Roeb, Elke
    Weiskirchen, Ralf
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [27] Non-alcoholic Steatohepatitis: An Overview
    Shifflet, Allison
    Wu, George Y.
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (01) : 4 - 12
  • [28] Statins in Non-alcoholic Steatohepatitis
    Torres-Pena, Jose D.
    Martin-Piedra, Laura
    Fuentes-Jimenez, Francisco
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [29] News on non-alcoholic steatohepatitis
    Roeb, E.
    Nitschmann, S.
    [J]. INTERNIST, 2022, 63 (02): : 238 - 242
  • [30] Metformin in non-alcoholic steatohepatitis
    Urso, R
    Visco-Comandini, U
    [J]. LANCET, 2002, 359 (9303): : 355 - 356